Skip to main content
SpringerLink
Log in

Adjuvante endokrine Therapie des Mammakarzinoms — ein Update

  • Topic_Mammakarzinom
  • Published:
best practice onkologie Aims and scope

Das Mammakarzinom ist die häufigste maligne Erkrankung der Frau. Jährlich erkranken in Deutschland etwa 70.000 Frauen an einem Mammakarzinom [24]. Durch die adjuvanten Therapien konnte die Mortalität in den letzten Jahren deutlich gesenkt werden [14]. Zu den adjuvanten Therapien zählen in erster Linie die endokrine Therapie bei hormonrezeptorpositivem Mammakarzinom sowie die Chemotherapie bei höherem Rezidivrisiko. Allein durch die adjuvante endokrine Therapie konnte das kumulative Sterberisiko über 15 Jahre signifikant um etwa 40 % gesenkt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. AGO Breast Committee (2014) Diagnosis and treatment of patients with primary and metastatic breast cancer. Recommendations. http://www.ago-online.de

  2. Amir E, Seruga B, Niraula S et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1–11

    Article  Google Scholar 

  3. Berndt U, Leplow B, Kantelhardt E et al (2009) Cognitive effects of systemic therapy in patients with breast cancer. Breast Care (Basel) 4:177–182

    Article  Google Scholar 

  4. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766–776

    Article  CAS  PubMed  Google Scholar 

  5. Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796

    Article  PubMed  Google Scholar 

  6. Coleman RE, Bolten WW, Lansdown M et al (2008) Aromatase inhibitor induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34:275–282

    Article  CAS  PubMed  Google Scholar 

  7. Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570

    Article  CAS  PubMed  Google Scholar 

  8. Craig MC, Fletcher PC, Daly EM et al (2008) A study of visuospatial working memory pre- and post-Gonadotropin Hormone Releasing Hormone agonists (GnRHa) in young women. Horm Behav 54:47–59

    Article  CAS  PubMed  Google Scholar 

  9. Cuzick J, Ambroisine L, LHRH-agonists in Early Breast Cancer Overview group et al (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormonereceptorpositive breast cancer: a meta-analysis of individual patient data from randomized adjuvant trials. Lancet 369(9574):1711–1723

    Article  CAS  PubMed  Google Scholar 

  10. Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141

    Article  CAS  PubMed  Google Scholar 

  11. Davies C, Pan H, Godwin J, Gray R et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor- positive breast cancer: ATLAS, a randomized trial. Lancet 381(9869):805–816

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7:223–229

    Article  CAS  PubMed  Google Scholar 

  13. Domchek SM, Friebel TM, Singer CF et al (2010) Association of riskreducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient level meta-analysis of randomised trials. Lancet 378(9793):771–784

    Article  CAS  PubMed  Google Scholar 

  15. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717

    Article  Google Scholar 

  16. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451–1467

    Article  Google Scholar 

  17. Goss PE, Ingle JN, Martino S et al (2009) Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 Trial. San Antonio Breast Cancer Symposium (abstract 13)

  18. Gray RG, Rea D, Handley K et al (2013) aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31 (suppl; abstr 5)

  19. Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Higgins MJ, Liedke PE, Goss PE (2013) Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCICCTGMA. 17/BIG 1-97 trial. Crit Rev Oncol Hematol 86:23–32

    Article  PubMed  Google Scholar 

  21. Ingle JN (2006) Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Clin Cancer Res 12(3 Pt 2):1031s–1036s

    Article  CAS  PubMed  Google Scholar 

  22. Jakesz R, Gnant M, Griel R et al (2008) Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. San Antonio Breast Cancer Symposium (abstract 14)

  23. Kaufmann M, Jonat W, Hilfrich J et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 25(19):2664–2670

    Article  CAS  PubMed  Google Scholar 

  24. Krebs in Deutschland 2009/2010. 9. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg). Berlin, 2013

  25. National Comprehensive Cancer Network®. NCCN Guidelines Version3.2013. Invasive Breast Cancer. Definition of Menopause (BINV-L). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Zugegriffen: 30. Juli 2013

  26. Ortmann O, Cufer T, Dixon JM et al (2009) Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast 18(1):2–7

    Article  PubMed  Google Scholar 

  27. Pagani O, Regan MM, Walley B et al (2014) Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol 32:5s (suppl; abstr LBA1)

  28. Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J Natl Cancer Inst 104(6):441–451

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8•1 years median follow-up. Lancet Oncol 12:1101–1108

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Smith IE, Dowsett M, Yap YS et al (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24:2444–2447

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Gynäkologie, Martin-Luther-Universität Halle, Ernst-Grube-Str. 40, 06120, Halle, Deutschland

    S. Steer

  2. Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Deutschland

    D. Lüftner

Authors
  1. S. Steer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Lüftner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Steer.

Additional information

Einhaltung ethischer Richtlinien

Interessenkonflikt.S. Steer gibt an, dass kein Interessenkonflikt besteht. D. Lüftner hat Vortragshonorare von Novartis, Pfizer und Astra Zeneca erhalten.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Steer, S., Lüftner, D. Adjuvante endokrine Therapie des Mammakarzinoms — ein Update. best practice onkologie 9, 6–11 (2014). https://doi.org/10.1007/s11654-014-0517-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-014-0517-y

Search

Navigation